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Abstract
Background: “Nubiotics” are synthetic oligonucleotides and nucleotides with nuclease-resistant backbones, and are
fully protonated for enhanced ability to be taken up by bacterial cells. Nu-3 [butyl-phosphate-5’-thymidine-3’-
phosphate-butyl], one of the family members of Nubiotics was efficacious in the treatment of burn-wound
infections by Pseudomonas aeruginosa in mice. Subsequent studies revealed that Nu-3 had a favorable toxicological
profile for use as a pharmaceutical agent. This study evaluated the antibacterial activity of Nu-3 in vitro and its
efficacy as a topical antibiotic. In addition, we investigated the possible mechanisms of Nu-3 action at the levels of
DNA synthesis and bacterial membrane changes.
Methods: Antimicrobial minimum inhibitory concentrations (MIC) experiments with Nu-3 and controls were
measured against a range of Gram-positive and Gram-negative bacteria, including some hospital isolates according
to Clinical and Laboratory Standards Institute (CLSI) guidelines. Analysis of the killing kinetics of Nu-3 was also
performed against two strains (Staphylococcus aureus cvcc 2248 and Pseudomonas aeruginosa cvcc 5668). The
mouse skin suture-wound infection model was used to evaluate the antibacterial activity of Nu-3. We used a
5-Bromo-2’-deoxy-uridine Labeling and Detection Kit III (Roche, Switzerland) to analyze DNA replication in bacteria
according to the manufacturer’s instruction. The BacLight™ Bacterial Membrane Potential Kit (Invitrogen) was used
to measure the bacterial membrane potential in S. aureus.
Results: Nu-3 had a wide antibacterial spectrum to Gram-positive, Gram-negative and some resistant bacteria.
The MIC values of Nu-3 against all tested MRSA and MSSA were roughly in a same range while MICs of Oxacillin
and Vancomycin varied between the bacteria tested. In the mouse model of skin wound infection study, the
treatment with 5% Nu-3 glycerine solution also showed comparable therapeutic effects to Ciprofloxacin
Hydrochloride Ointment. While Nu-3 had no effect on DNA synthesis of the tested bacteria as demonstrated in
a BrdU assay, it could cause bacterial cell membrane depolarization, as measured using a BacLight™ Bacterial
Membrane Potential Kit.
Conclusions: These results provide additional experimental data that are consistent with the hypothesis that Nu-3
represents a new class of antibacterial agents for treating topical infections and acts via a different mechanism
from conventional antibiotics.
Background
Microorganisms resistant to multiple anti-infective
agents have increased around the world [1]. Bacterial
resistance in community settings has also become a
great concern and Methicillin-resistant Staphylococcus
aureus (MRSA) is a frequent cause of health care- and
community-associated infections. This is especially true
in countries with limited resources [2,3]. Ecological
pressure derived from the use of antimicrobial agents is
the main driving force for the emergence of the resis-
tance. Heroic efforts has been made both in academic
institutions and pharmaceutical industries in response to
the increasing medical need and to increasing resistance
of bacteria to both individual classes of antibiotics and
especially across different classes [4]. Unfortunately, the
development of new antibiotics has not kept pace with
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any medium, provided the original work is properly cited.the increase in prevalence of multi-drug resistant patho-
gens. To reduce the human mortality and morbidity
associated with the infectious diseases caused by drug-
resistant bacterial pathogens, there is a compelling need
to develop new therapeutic agents that are effective
against drug-resistant mutants [5].
“Nubiotics” are synthetic oligonucleotides and nucleo-
tides with nuclease-resistant backbones, and are fully
protonated for enhanced ability to be taken up by
bacterial cells. Nu-3 [butyl-phosphate-5’-thymidine-3’-
phosphate-butyl], one of the family members of Nubio-
tics, is a fully protonated and protected deoxynucleotide
and its chemical structure is shown in Figure 1. Previous
studies demonstrated that Nu-3 was efficacious in the
treatment of burn-wound infections by Pseudomonas
aeruginosa in mice [6]. Subsequent studies revealed that
there was no chronic toxicity to healthy mouse skin
when Nu-3 was applied topically [7], indicating that Nu-
3 has a favorable toxicological profile for use as a topical
antibiotic. In order to further explore how wide the
spectrum of Nu-3 antibacterial activity is, MIC and
time-kill experiments were performed with a wide range
of Gram-positive and Gram-negative bacteria, including
some hospital isolates of meticillin-resistent Staphylococ-
cus aureus (MRSA) and meticillin-susceptible Staphylo-
coccus aureus (MSSA). In addition, we evaluated
Nu-3 antibacterial activity in a mouse skin suture-
wound infection model against both the gram positive
(Staphylococcus aureus) and the gram negative (Pseudo-
monas aeruginosa) infections. We also investigated the
possible mechanisms of Nu-3 action at the levels of
DNA synthesis and bacterial membrane changes.
Materials and methods
Animals
BALB/c mice (females, 18-20 g, 8 weeks, from Vitalriver
Animal Center, Beijing), along with original breeding
pairs purchased from Charles River (Canada), were
housed under normal conditions for 5-7 days before
being used for experiments. The use and care of the ani-
mals were performed according to the Regulations for
the Administration of Affairs Concerning Experimental
Animals in China (11/14/1988).
Bacteria
The test organisms (Brucella abortus, Burkholderia mal-
lei, Burkholderia pseudomallei, Bacillus anthracis, Fran-
cisella tularensis, Yersinia pestis)f o rt h eM I Ca s s a y s
were recent, predominantly ocular, isolates of United
States origin. Five MRSA isolates consisted of non-
consecutive, non-duplicate clinical isolates collected
from Stanford University. Staphylococcus aureus (cvcc
2248) and Pseudomonas aeruginosa (cvcc 5668) were
purchased from China Institute of Veterinary Drug Con-
trol (CIVDC). These two isolates were collected from
the dermatology department of Peking Union Medical
Figure 1 Chemical structure of Nu-3.
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ATCC 25923, P. aeruginosa ATCC 27853, MSSA ATCC
29213, MRSA ATCC 33591 and S. aureus ATCC
700699 GISA. The bacterium was initially cultured on
trypticase soy broth (TSB), divided into aliquots, and
frozen at -80°C. Prior to use, aliquots were thawed and
diluted serially in sterile phosphate-buffered saline
(PBS). To ensure viability and virulence, aliquots of the
bacteria were periodically re-amplified in TSB and colo-
nies determined on trypticase soy agar (TSA) plates.
Antimicrobial agents
Nu-3 was synthesized and purified at Oligos Etc., Inc.
(Oregon) with 99.5% purity (HPLC). The concentration
of the agent was determined based on OD260 reading.
Ciprofloxacin, Oxacillin and Vancomycin were pur-
chased from Sigma (St. Louis, MO, USA). Ciprofloxacin
Hydrochloride Ointment (30 mg active ingredient per
10 grams) was purchased from TongRenTang Drug
Store (Beijing).
Determination of minimal inhibitory concentration (MIC)
MICs were determined using a standard 2-fold micro-
dilution method in Mueller-Hinton broth (Difco) and
antibacterial susceptibilities were reported using CLSI
interpretive criteria [8-10]. The highest drug concentra-
tion of Nu-3 tested in this assay was 2000 A/ml (117.6
mg/ml). To each well of a 96 well microtiter plate, 30 μl
of the different dilutions and 170 μl of MHB medium
containing 10
6 bacteria/ml were added. Plates containing
Burkholderia, Brucella and Francisella were incubated at
37°C with 5% CO2. The incubation time for Brucella
was 48 hours while Francisella and Yersinia were incu-
bated a total of >72 hours. The remaining strains of
Bacillus, Staphylococcus and Pseudomonas were incu-
bated for 24 hours at 37°C. Plates were scored and
numerical values were given to represent the extent of
growth. We scored “3” for maximum growth, “2” for
moderate growth, “1” for minimum growth and “0” for
no growth. The MIC was defined as the minimum
amount of Nu-3 that resulted in no visible growth after
incubation.
Time-progression curve for bacterial killing
The determination of the killing curve was carried out
as described previously with the following modifications
[11]. Briefly, aliquots of the bacterial suspension were
removed from the -80°C freezer and thawed at room
temperature.10 ul of the bacterial suspension was inocu-
lated in a tube with 5 ml TSB (BD) and then incubated
at 35°C with gentle shaking. The doses of Nu-3 and
Ciprofloxacin were added to the culture tubes at 2 ×
MIC, 1 × MIC (final concentration). Rates of killing
were determined by measuring the reduction in the
number of viable bacteria (ΔCFU/ml log10)a t0 ,2 ,4 ,6 ,
12, and 24 h at the fixed concentrations of Nu-3.
Experiments were performed in duplicate. If plates con-
tained fewer than 30 CFU/ml, then the number of colo-
nies was considered to be below the limit of
quantization [11]. Samples of cultures containing Nu-3
were diluted at least 10-fold to minimize drug carryover
to the TSA (BD) plates.
Mouse wound infection model
The establishment of the skin suture-wound model was
carried out as described previously [12]. Briefly, sterile
silk sutures were cut into 10-cm lengths and threaded
onto sterile surgical needles, followed by being soaked
for 45 min in undiluted broth cultures of the S. aureus
2248 and P. aeruginosa 5668 that had been incubated at
35°C for 8 h. The sutures with sterile surgical needles
were removed aseptically, dried on sterile filter paper at
4°C until the animals were prepared for surgery. Ani-
mals were anesthetized with 50 mg/kg Zoletil-50 (Vir-
bac, France) intramuscularly. The fur on the back and
flanks was clipped, and the skin was swabbed with 70%
ethanol. Before inoculating the suture, the knot was
made on one side of the suture. By using the threaded
needle, a 1-cm length of inoculated suture was inserted
under the skin of the mid-back and secured by knotting
on the other side of the suture. An incision was made
a l o n gt h el e n g t ho ft h es u t u r eb e t w e e nt h et w ok n o t s .
The depth of the incision did not reach into the panni-
culus carnosus. One wound was created per animal. To
count the bacteria carried on the sutures, 1-cm length
of each suture was vortexed in 1 ml of TSB (BD) for
15 min for the S. aureus 2248 and P. aeruginosa 5668.
The suspensions were serially diluted, and 10-ul of each
dilution was plated onto TSA (BD) in triplicate, and
then the plates were incubated for 24 h. The numbers
of organisms per centimeter on each suture were
calculated.
Nu-3 treatment of animals
To treat the infected mouse, 5% (50 mg Nu-3 in 1 ml
60% glycerin solutions) and 1% (10 mg Nu-3 in 1 ml
60% glycerin solutions) of Nu-3 glycerin solutions were
made in sterile water. Nu-3 glycerin solutions (100 μl)
and Ciprofloxacin Hydrochloride Ointment (0.2 g) were
applied topically onto the infection sites. Infected con-
trol mice without drug treatment were given an equal
volume of phosphate buffered saline (PBS) and glycerin
water solutions. Treatment was initiated 4 h after sur-
gery and a second application was made 8 h later. The
treatment was continued three times daily for a further
3 days. At 5 days post treatment, the mice were eutha-
nized by zoletil-50 overdose. A 1-by-1-cm area of skin,
including the wound, was excised and homogenized in
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were serially diluted, and the organisms were numerated
as previously described.
BrdU incorporation Assay
We used a 5-Bromo-2’-deoxy-uridine Labeling and
Detection Kit III (Roche, Switzerland) to analyze DNA
replication in bacteria according to the manufacturer’s
instruction. In brief, Nu-3 in a range of concentrations
was added to the testing bacteria. 100 ul per well of the
treated bacteria suspension (ca. 6 × 10
6 CFU/ml for
S. aureus 2248) was added into a 96-well microplate,
and 10 ul BrdU labeling solution added to each well,
then incubated for 8 h at 37°C. The suspension was
spun for 10 min at 300 × g in a microcentrifuge (Eppen-
dorf, Germany) and the labeling medium was carefully
removed. The bacteria were allowed to dry at the bot-
tom of the microplate for 2 h at 60°C and then fixed
with 200 ul pre-cooled fixative per well for 2 h at -20°C.
After removal of the fixative, the plate was washed 3
times with 250 ul PBS, followed by adding 100 ul of
nucleases working solution per well and incubating the
mixture for 30 min at 37°C water bath. The nucleases
working solution was then removed and washed 3 times
with 250 ul PBS. To the each well, 100 ul anti-BrdU-
POD working solution was added and incubated for 30
min at 37°C. The antibody conjugate was removed by 3
washes with 250 ul washing buffer and 100 ul peroxi-
dase substrate with substrate enhancer per well was
added and incubated at room temperature for 15 min.
Finally, extinction of the samples was measured in a
microplate reader at 405 nm with a reference wave-
length at 490 nm as the rate of incorporation of BrdU
into bacterial DNA. In the study, we used Ciprofloxacin
as a positive control since fluoroquinolones acts by
interacting with type II topoisomerases (DNA gyrase
and topoisomerases IV) to inhibit DNA synthesis [13].
Measurement of bacterial membrane potential
The BacLight™ Bacterial Membrane Potential Kit (Invi-
trogen) was used to measure the bacterial membrane
potential in S. aureus. Diethyloxacarbocyanine (DiOC2)
exhibits green fluorescence in all bacterial cells, but the
fluorescence shifts toward red emission as the dye mole-
cules self associate at - higher cytosolic concentrations
caused by larger membrane potentials. Proton iono-
phores such as carbonyl cyanide m-chlorophenylhydra-
zone (CCCP) could destroy membrane potential by
eliminating the proton gradient, thus it was used as a
positive control in the study. The ratio of red to green
fluorescence provides a measure of membrane potential
that is largely independent of cell size, with a low coeffi-
cient of variation (CV) [14]. Bacteria was grown in
TSB (BD) overnight and diluted in filtered PBS to
approximately 1 × 10
6 CFU/ml. Aliquots of 1 ml bacter-
ial suspension were added into flow cytometry tubes for
staining treatments with a depolarized control and an
unstained control. 100 μl of Nu-3 in a range of concen-
trations was added to each sample tube, and 10 μlo f
500 uM CCCP to the depolarized control sample. All
samples were then incubated for 30 min at 4°C, followed
by adding 5 μlo f3m MD i O C 2 to each flow cytometry
tube, mixing well and incubating at room temperature
for 15 minutes. Stained bacteria were assayed in a flow
cytometer (BD) with a laser emitting at 488 nm. Fluor-
escence was collected in the green and red channels
("GC” and “RC”); the unstained control sample was used
to locate bacterial populations in the forward and side
scatter channels. The bacteria population was gated
using forward versus side scatter and fluorescence
photomultiplier tube voltages were adjusted such that
the green and red MFI values were approximately equal
without compensation. While the relative amount of red
and green fluorescence intensity varied with respect to
cell size and aggregation, the ratio of red to green flores-
cence intensity can be used as a size-independent indi-
cator of membrane potential. For a dot plot of red
versus green fluorescence, the regions around the popu-
lations of interest were set and red and green MFI
values for each recorded. The change of the membrane
potential was expressed as MFI of the red population
divided by the green population MFI.
Statistical analysis
Statistical analysis of the bacterial counts between con-
t r o la n dt e s tg r o u p sw a sc a r r i e du s i n go n e - w a y
ANOVA. Significance was evaluated at p-value of 0.05.
Results and discussion
Antibacterial activity of Nu-3 in vitro
To determine the spectrum of Nu-3 antibacterial activ-
ity, antimicrobial minimum inhibitory concentrations
(MIC) of Nu-3 and controls against a range of Gram-
positive and Gram-negative bacteria, including some
hospital isolates of meticillin-resistent Staphylococcus
aureus (MRSA) and meticillin-susceptible Staphylococ-
cus aureus (MSSA), were performed. The results showed
that Nu-3 had a wide antibacterial spectrum to Gram-
positive, Gram-negative and some resistant bacteria
(Table 1). The MIC values of Nu-3 against all tested
MRSA isolates were roughly in a same range while
MICs of Oxacillin and Vancomycin varied between the
bacteria tested. These data suggested that Nu-3 may act
in a different mechanism from the conventional
antibiotics.
Time-kill assays were conducted for Staphylococcus
aureus 2248 and Pseudomonas aeruginosa 5668 in con-
centrations of 2 × MIC, and 1 × MIC. Figure 2 and
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and vancomycin)
MIC
Strains Nu-3 (mg/ml) Ciprofloxacin (μg/ml) Oxacillin (μg/ml) Vancomycin (μg/ml)
Brucella abortus >2.2 1 - -
Burkholderia mallei >4.4 1 - -
Burkholderia pseudomallei 4.4 1 - -
Bacillus anthracis (Sterne) 2.2 0.08 - -
Francisella tularensis 2.2 0.08 - -
Yersinia pestis 4.4 0.16 - -
Staphylococcus aureus cvcc 2248 4.4 8 - -
Pseudomonas aeruginosa cvcc 5668 8.8 4 - -
MSSA ATCC 29213 8.8 - 0.4 1
MRSA ATCC 33591 >4.4 - 256 2
S. aureus ATCC 700699 GISA 8.8 - >32 32
Stanford University MRSA Clinical Isolate #1 >4.4 - 256 2
Stanford University MRSA Clinical Isolate #2 8.8 - 128 1
Stanford University MRSA Clinical Isolate #3 8.8 - >256 4
Stanford University MRSA Clinical Isolate #4 8.8 - 32 1
Stanford University MRSA Clinical Isolate #5 8.8 - 32 1
MRSA: meticillin-resistant Staphylococcus aureus.
Figure 2 Time-progression curves of killing S. aureus cvcc 2248 in different concentrations of Nu-3 (open circles: 1 × MIC; cross: 2 ×
MIC) and ciprofloxacin (CIP) (open diamonds: 1 × MIC; open triangle: 2 × MIC). Open squares: no-treatment growth control. The average
values ± SD were used in the figure.
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Staphylococcus aureus 2248 and Pseudomonas aerugi-
nosa 5668 at 2, 4, 6, 12 and 24 h after the addition of
Nu-3 and Ciprofloxacin. It revealed that those two
strains had a similar time-kill profile with Nu-3 killing
S. aureus 2248 and P. aeruginosa 5 6 6 8a tav e r yf a s t
rate. In concentration-dependent killing of S. aureus
2248, a 1000-fold reduction in CFU was observed after
2 h for Nu-3 (2 × MIC) and a 100-fold reduction for
ciprofloxacin (2 × MIC). In the concentration-dependent
killing of P. aeruginosa 5668, a 1000-fold reduction in
CFU was observed after 4 h for Nu-3 and ciprofloxacin
(2 × MIC). When a dose of 1 × MIC of Nu-3 and cipro-
floxacin was used, a 1000-fold reduction in CFU was
observed at 4 h for Nu-3, but it needed 12 h to reach
the same level of reduction in CFU for ciprofloxacin.
For Nu-3, the CFUs from S. aureus 2248 and P. aerugi-
nosa 5668 were reduced to zero within 6 h at both 2 ×
MIC and 12 h at 1 × MIC while for Ciprofloxacin, the
time to zero in CFU was 12 h (2 × MIC) for both
strains. These data suggest that Nu-3 can kill bacteria at
a faster rate than ciprofloxacin at concentrations of both
2 × MIC and 1 × MIC.
Therapeutic efficacy of Nu-3 in mouse wound model
To evaluate potency of Nu-3 in vivo, the skin suture-
wound model was used to topically test the antibacterial
activity of Nu-3 [12]. First, we examined if Nu-3 could
treat the wound infection in a dose-response manner.
As shown in Table 2, Nu-3 glyerine solution could inhi-
bit the growth of both P. aeruginosa and S. aureus in
vivo. This inhibitory effect showed a dose-response with
1 log (1% Nu-3) and 2 log (5% Nu-3) reduction in CFU
values in comparison with the untreated control (P <
0.01 and P < 0.001 respectively). We then compared
Nu-3 with Ciprofloxacin Hydrochloride Ointment in
their effect on the bacterial growth. Both Nu-3 and
Ciprofloxacin gel showed a similar therapeutic effect in
Figure 3 Time-progression curves of killing P. aeruginosa cvcc 5668 in different concentrations of Nu-3 (open circles: 1 × MIC; cross:
2 × MIC) and ciprofloxacin (CIP) (open diamonds: 1 × MIC; open triangle: 2 × MIC). Open squares: no-treatment growth control. The
average values ± SD were used in the figure.
Cao et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:1
http://www.ann-clinmicrob.com/content/10/1/1
Page 6 of 9the skin suture-wound model, as compared with the
untreated animals (P < 0.001) (Table 3). Nu-3 in gly-
cerin formulation appeared to be slightly better than
that in saline although the difference was not statistically
significant.
The mouse model of skin wound infection was estab-
lished by implanting contaminated sutures [15]. This
model represents the secondary skin infections that may
occur following damage by accidental trauma, and sur-
gery. The skin is a milieu for controlled bacterial
growth. Resident gram-positive bacteria include Staphy-
lococcus aureus and Streptococcus pyogenes are notor-
iously pathogenic in the skin [16]. Pseudomonas
aeruginosa is an opportunistic pathogen found along
with other Pseudomonas spp. as part of the normal flora
of the human skin [17]. When the host is immunocom-
promised, as in the case of a surgical wound, this oppor-
tunistic bacterium can quickly colonize and infects the
wound site and then penetrates the blood capillaries of
the affected tissues and thus may lead to bacteremia.
Moreover, the virulence factors which the bacteria pro-
duced can lead to endotoxic shock. Once reaching the
bacteremia or endotoxic shock phase, wound infections
are generally beyond treatment by conventional antibio-
tic therapy. Therefore, it is imperative that effective
antibiotic treatment be administered at an early stage of
infection to be efficacious. In the present study, two
treatments were applied at 4 h and 8 h after surgery to
eliminate the bacteria at an early stage. During 5 days of
the observation, the bacterial count from each wound
increased to 10
7 at the 5
th day from an initial inocula-
tion with 10
4 bacteria of either strains in the untreated
and placebo groups. Topical treatment with 1-5% Nu-3
glycerine solution significantly reduced the numbers of
P. aeruginosa 5668 and S. aureus 2248 CFU after the
treatment (Table 2 and 3). These data clearly show that
the established topical treatment is effective in this
model. The treatment with 5% Nu-3 glycerine solution
also showed comparable therapeutic effects to Cipro-
floxacin Hydrochloride Ointment. Therefore, Nu-3 may
represent a promising externally applied agent for treat-
ing wound infection.
Possible mechanisms of action of Nu-3
Modes of action for antimicrobials vary depending on
their biochemical properties. The major mechanisms of
action for antibiotics include inhibiting protein synth-
esis, nucleic acid synthesis and selectively disrupting
bacterial metabolism. Chemically, Nu-3 is a modified
nucleotide, which could potentially affect nucleic acid
synthesis and function, and less likely interfere with
other biological processes. Thus, we investigated if Nu-3
had any impact on nucleic acid synthesis by using BrdU
incorporation assay. In addition, since Nu-3 is a proto-
nated molecule, it is possible that Nu-3 may act through
changing membrane polarity.
Effect of Nu-3 on DNA synthesis
The incorporation of 5-Bromo-2’-deoxy-uridine (BrdU)
was monitored as a parameter for DNA synthesis and
cellular proliferation. Cells that have incorporated BrdU
into DNA can be easily detected using a monoclonal
antibody against BrdU [18]. As shown in Figure 4, in a
r a n g eo fN u - 3c o n c e n t r a t i o n s( 0 . 5×M I C ,0 . 2 5×M I C ,
0.125 × MIC and 0.0625 × MIC), the testing compound
did not inhibit the incorporation of BrdU into the
Table 2 Dose-response of Glycerin-Nu-3 solution in
inhibition of P. aeruginosa cvcc 5668 and S. aureus cvcc
2248 growth in mouse suture-wound model
Mean bacterial counts ± SD (Log10CFU/
wound)
a
Treatments P. aeruginosa cvcc5668 S. aureus cvcc2248
Initial innoculation 4.66 ± 0.12 4.88 ± 0.56
Untreated 7.24 ± 0.30 7.18 ± 0.57
Glycerin solution 6.86 ± 0.19 7.04 ± 0.48
1% Nu-3 in Glycerin 6.73 ± 0.27* 6.34 ± 0.32*
5% Nu-3 in Glycerin 5.76 ± 0.42** 4.95 ± 0.21**
a, n = 6; *P < 0.01; **P < 0.001 in comparison with the untreated control. 5%
Nu-3 is equivalent to 50 mg Nu-3 in 1 ml 60% glycerin solutions and 1% Nu-3
is 10 mg Nu-3 in 1 ml 60% glycerin solutions.
Table 3 Comparative study of Nu-3 against P. aeruginosa cvcc 5668 and S. aureus cvcc 2248 with Ciprofloxacin in
mouse suture wound model
Treatments Mean bacterial counts ± SD (Log10CFU/wound)
a
P. aeruginosa cvcc5668 S. aureus cvcc2248
Initial innoculation 4.93 ± 0.33 4.79 ± 0.31
Untreated 7.52 ± 0.57 7.64 ± 0.58
Glycerin solution 7.34 ± 0.27 7.47 ± 0.34
5% Nu-3 in saline 5.62 ± 0.61** 5.23 ± 0.5**
5% Nu-3 glycerin solution 5.07 ± 0.53** 4.51 ± 0.55**
Ciprofloxacin hydrochloride ointment 4.82 ± 0.58** 5.63 ± 0.31**
a, n = 6; **P < 0.001 in comparison with the untreated control. 5% Nu-3 is equivalent to 50 mg Nu-3 in 1 ml 60% glycerin solutions and 1% Nu-3 is 10 mg Nu-3
in 1 ml 60% glycerin solutions.
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incorporation rate between each Nu-3 treated group,
while ciprofloxacin as a positive control could inhibit
DNA synthesis in the tested concentrations. The maxi-
mum concentration used in the study was 0.5 × MIC
and the reason for this was that higher concentrations
of Nu-3 may inhibit the growth of bacteria. The results
clearly indicated that the Nu-3 action was not via inter-
ference to DNA synthesis. This can be easily compre-
hended in that Nu-3 is a modified thymidine with the
phosphate-groups at both the 5’-a n d3 ’-ends. (butyl-
phosphate-5’-thymidine-3’-phosphate-butyl). It is unli-
kely that Nu-3 could compete with dTTP in the cellular
environment to be incorporated into DNA during bac-
terial proliferation.
Effect of Nu-3 on bacterial membrane potential
In order to study the other potential mechanisms, the
BacLight™ Bacterial Membrane Potential Kit was used
to measure the bacterial membrane potential. It is
known that changes in both green florescence (530 nm)
and red fluorescence (600 nm) of the fluorescent dye
DiOC2 (3) can reflect changes in membrane potential
[19]. As shown in Figure 5A, 5 mg/ml and 10 mg/ml
Nu-3 exhibited a similar absorption profile to the posi-
tive control CCCP, which is a proton ionophore and
depolarized the cell membrane. Quantitatively, the ratio-
metric parameter (red/green) of both Nu-3 and CCCP
Figure 4 Assays were performed in a 96-well microplate with
triplicates for each sample. Data were from three independent
experiments and expressed as average ± SD. The concentration of
Nu-3 and ciprofloxacin (CIP) in this assay were 0.5 × MIC, 0.25 ×
MIC, 0.125 × MIC and 0.0625 × MIC and the tested bacteria was
S. aureus cvcc 2248. **P < 0.001 in comparison with the control.
Figure 5 Detection of the membrane potential in S. aureus. A: The red-versus-green fluorescence dot plot. B: The bar charts showed the
red/green ratios in different treated groups. Ratiometric parameter was calculated using population mean fluorescence intensities from FACS
data of counts vs FL1-H or FL2-H respectively. FL1-H: green fluorescence intensities; FL2-H: red fluorescence intensities.
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untreated cells (Figure 5B). This result suggests that
Nu-3 might inhibit bacterial growth via a membrane
depolarization mechanism.
In metabolically active bacteria with intact cytoplasmic
membranes, there is typically a difference of electrical
potential across the membrane, with the interior nega-
tive by between 100 and 200 mV with respect to the
exterior. This electrical potential is referred to as resting
potential. A reduction in the magnitude of the mem-
brane potential is referred to as electrical depolarization:
an increase in the magnitude of membrane potential is
referred to as electrical hyperpolarization. In this study,
we, for the first time, show that Nu-3 could change the
membrane potential that caused depolarization, possibly
leading to the cell disruption, which was clearly shown
in the bacterial cells using FACS (Figure 5) and fluores-
cence microscopy (data not shown). Therefore, this sug-
gests that the membrane depolarization could be one of
the mechanisms of antibacterial activity of Nu-3.
Conclusions
In conclusion, the present study presented experimental
evidence that supports the further development of Nu-3
as a novel antibiotic for topical uses in various applica-
tions, such as wound healing. With improved formula-
tions and delivery means, for example, using liposome
and nanoparticles, we hoped that better therapy can be
provided for bacterial infections, particularly for existing
drug-resistant strains.
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